• CorMedix Inc. has reported past fourth-quarter 2025 revenue of US$128.62 million and net income of US$14.02 million, capping a year in which full-year revenue reached US$311.71 million and net income swung to US$163.06 million from a prior loss.
• The company’s reiteration of 2026 net revenue guidance of US$300 million to US$320 million, alongside advancing late-stage trials for REZZAYO and other pipeline assets, highlights management’s focus on consolidating recent product gains while preparing for potential new revenue sources.
• Next, we’ll examine how reaffirming 2026 revenue guidance at US$300–US$320 million reshapes CorMedix’s existing investment narrative and risk profile.

We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

CorMedix Investment Narrative Recap

To own CorMedix today, you need to believe its newly profitable anti infectives platform can outlast reimbursement pressure on DefenCath while unlocking fresh contribution from late stage assets like REZZAYO. The latest results and reaffirmed 2026 revenue guidance look largely incremental to that core thesis, but they keep the near term focus squarely on Phase III REZZAYO data and on how DefenCath pricing and usage evolve under changing Medicare rules, which remain the central catalyst and risk.

Among recent developments, the reiterated 2026 net revenue guidance of US$300 million to US$320 million is most relevant here, because it frames how management currently sees the balance between maturing DefenCath sales, integration of Melinta’s portfolio and pending trial readouts. That range now serves as a reference point for judging any upside or downside that could stem from REZZAYO data or reimbursement decisions, and for assessing whether current expectations already reflect the key near term catalysts.

Yet behind the strong 2025 numbers and steady 2026 outlook, the real question investors should be aware of is how future reimbursement shifts could...

CorMedix's narrative projects $433.6 million revenue and $244.7 million earnings by 2028. This implies 52.8% yearly revenue growth and about a $193.5 million earnings increase from $51.2 million today.

Uncover how CorMedix's forecasts yield a $14.86 fair value, a 130% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were once modeling CorMedix revenue climbing toward about US$568 million with earnings near US$299 million, yet if real world evidence or reimbursement outcomes fall short of those hopes, your view on the stock could end up very different from theirs.

Explore 8 other fair value estimates on CorMedix - why the stock might be worth just $14.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CorMedix research is our analysis highlighting 5 key rewards and 3 important warning signs that could impact your investment decision.
• Our free CorMedix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CorMedix's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.